<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5546434</article-id><article-id pub-id-type="pmid">28620146</article-id><article-id pub-id-type="publisher-id">18460</article-id><article-id pub-id-type="doi">10.18632/oncotarget.18460</article-id><article-categories><subj-group subj-group-type="heading"><subject>Priority Research Paper</subject></subj-group></article-categories><title-group><article-title>Mitochondrial ASncmtRNA-1 and ASncmtRNA-2 as potent targets to inhibit tumor growth and metastasis in the RenCa murine renal adenocarcinoma model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Borgna</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villegas</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Burzio</surname><given-names>Ver&#x000f3;nica A.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Belmar</surname><given-names>Sebasti&#x000e1;n</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Araya</surname><given-names>Mariela</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jeldes</surname><given-names>Emanuel</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lobos-Gonz&#x000e1;lez</surname><given-names>Lorena</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Ver&#x000f3;nica</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villota</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oliveira-Cruz</surname><given-names>Luciana</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>Constanza</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Socias</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Castillo</surname><given-names>Octavio</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Burzio</surname><given-names>Luis O.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Andes Biotechnologies SpA, Santiago, Chile</aff><aff id="A2"><sup>2</sup> Fundaci&#x000f3;n Ciencia &#x00026; Vida, &#x000d1;u&#x000f1;oa, Santiago, Chile</aff><aff id="A3"><sup>3</sup> Servicio de Urolog&#x000ed;a, Hospital Barros Luco-Trudeau, Universidad de Santiago, Santiago, Chile</aff><aff id="A4"><sup>4</sup> Facultad de Ciencias Biol&#x000f3;gicas, Universidad Andr&#x000e9;s Bello, Santiago, Chile</aff><aff id="A5"><sup>5</sup> Facultad de Salud, Universidad Bernardo O Higgins, Santiago, Chile</aff><aff id="A6"><sup>6</sup> Centro de Cirug&#x000ed;a Rob&#x000f3;tica, Cl&#x000ed;nica Indisa, Santa Mar&#x000ed;a, Santiago, Chile</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Vincenzo Borgna,</italic><email>vborgna@gmail.com</email></corresp><corresp id="cor2"><italic>Ver&#x000f3;nica A. Burzio,</italic><email>vburzio@gmail.com</email></corresp><corresp id="cor3"><italic>Jaime Villegas,</italic><email>jvillegas@bioschile.cl</email></corresp><corresp id="cor4"><italic>Luis O. Burzio,</italic><email>lburzio@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><day>4</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>13</day><month>6</month><year>2017</year></pub-date><volume>8</volume><issue>27</issue><fpage>43692</fpage><lpage>43708</lpage><history><date date-type="received"><day>14</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Borgna et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License 3.0</ext-link> (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Knockdown of antisense noncoding mitochondrial RNAs (ASncmtRNAs) induces apoptosis in several human and mouse tumor cell lines, but not normal cells, suggesting this approach for a selective therapy against different types of cancer. Here we show that <italic>in vitro</italic> knockdown of murine ASncmtRNAs induces apoptotic death of mouse renal adenocarcinoma RenCa cells, but not normal murine kidney epithelial cells. In a syngeneic subcutaneous RenCa model, treatment delayed and even reversed tumor growth. Since the subcutaneous model does not reflect the natural microenviroment of renal cancer, we used an orthotopic model of RenCa cells inoculated under the renal capsule. These studies showed inhibition of tumor growth and metastasis. Direct metastasis assessment by tail vein injection of RenCa cells also showed a drastic reduction in lung metastatic nodules. <italic>In vivo</italic> treatment reduces survivin, N-cadherin and P-cadherin levels, providing a molecular basis for metastasis inhibition. In consequence, the treatment significantly enhanced mouse survival in these models. Our results suggest that the ASncmtRNAs could be potent and selective targets for therapy against human renal cell carcinoma.</p></abstract><kwd-group><kwd>murine renal cancer</kwd><kwd>ncRNA</kwd><kwd>mitochondria</kwd><kwd>antisense therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Renal cell carcinoma (RCC) constitutes almost 3% of all malignant tumors in adults. According to recent statistics, 62,700 new cases and 14,240 deaths by RCC in female and male patients were expected in the United States in 2016 [<xref rid="R1" ref-type="bibr">1</xref>]. The overall 5-yr survival rate of localized RCC patients is about 93% and standard therapy is partial or radical nephrectomy [<xref rid="R1" ref-type="bibr">1</xref>]. Similar statistics have been reported in Europe [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. Metastatic RCC (mRCC) holds a poor prognosis and patients face limited therapeutic options [<xref rid="R4" ref-type="bibr">4</xref>]. The first-line treatment for mRCC is the multi-tyrosine kinase inhibitor sunitinib, which displays only a modest therapeutic potential [<xref rid="R5" ref-type="bibr">5</xref>]. Several other treatments have been described, such as the mTOR inhibitor temsirolimus [<xref rid="R6" ref-type="bibr">6</xref>] and high-dose IL-2 [<xref rid="R7" ref-type="bibr">7</xref>], which also display low efficacy, in addition to high toxicity. Immunotherapy with a monoclonal antibody against VEFG1 and VEFG2 (VEGF-Trap) showed a significant reduction of 74% in tumor size, but without complete tumor remission [<xref rid="R8" ref-type="bibr">8</xref>]. On the other hand, combined therapy with histone deacetylase inhibitors and high-dose IL-2 reduced tumor growth from 1900 mg to 200 mg considering however the toxicity of IL-2 [<xref rid="R9" ref-type="bibr">9</xref>]. Sequential treatment with sunitinib followed by everolimus in an orthotopic RenCa model led to a modest reduction in both primary tumors and metastatic foci. These effects were not observed with sunitinib alone or followed by sorafenib, which are currently used as first- and second-line therapies against mRCC [<xref rid="R10" ref-type="bibr">10</xref>]. Therefore, there is an urgent need to find new non-toxic and effective therapeutic approaches for mRCC.</p><p>Human cells express a unique family of sense (SncmtRNA) and antisense ASncmtRNAs) non-coding mitochondrial RNAs [<xref rid="R11" ref-type="bibr">11</xref>&#x02013;<xref rid="R13" ref-type="bibr">13</xref>]. The SncmtRNA is expressed in normal proliferating cells and tumor cells, but not in resting cells, suggesting a role for this transcript in cell proliferation [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. Normal proliferating cells also express two antisense transcripts: ASncmtRNA-1 and ASncmtRNA-2 [<xref rid="R12" ref-type="bibr">12</xref>]. Remarkably however, the ASncmtRNAs are downregulated in human and mouse tumor cell lines, including mouse RenCa cells [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R14" ref-type="bibr">14</xref>]. Thus, it seems that at least in these two mammalian species, downregulation of the ASncmtRNAs seems to be an important step in carcinogenesis and represents a new and generalized pro-tumorigenic hallmark of cancer [<xref rid="R15" ref-type="bibr">15</xref>].</p><p>Knockdown of human ASncmtRNAs (ASK for short) <italic>in vitro</italic> using antisense oligonucleotides (ASOs) induces apoptotic cell death of a wide array of human cancer cell lines from several tissue origins [<xref rid="R16" ref-type="bibr">16</xref>]. Similarly, we reported recently that ASK <italic>in vitro</italic> also induces apoptotic cell death of the aggressive murine melanoma cell line B16F10, together with downregulation of survivin, an important member of of the AIP family [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>&#x02013;<xref rid="R21" ref-type="bibr">21</xref>]. Moreover, using a syngeneic subcutaneous B16F10 melanoma model, we reported that ASK induces a drastic inhibition of tumor growth and lung and liver metastasis suggesting that the ASncmtRNAs are potent targets to develop a new treatment for melanoma [<xref rid="R14" ref-type="bibr">14</xref>]. However, oligonucleotides are not able to enter mitochondria <italic>in vivo</italic> [<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref>]. Therefore, the effective effect of ASO in cells and <italic>in vivo</italic> is because, in human and murine tumor and normal cells, the SncmtRNA and the ASncmtRNAs exit the mitochondria and are found localized in the cytoplasm and the nucleus [<xref rid="R24" ref-type="bibr">24</xref>].</p><p>Here we show that ASK induces apoptotic cell death in the RenCa murine RCC cell line. Translation of these results to <italic>in vivo</italic> syngeneic RCC assays (subcutaneous, orthotopic and tail vein inoculation), showed that ASK inhibits tumor growth and lung metastasis, suggesting that the ASncmtRNAs might be potent targets for human RCC therapy.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Expression of the mitochondrial lncRNAs</title><p>As the human transcripts, murine ncmtRNAs should arise from the bidirectional transcription [<xref rid="R25" ref-type="bibr">25</xref>] of the mitochondrial genome and processing of segments from the 16S rRNA gene [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. Figure <xref ref-type="fig" rid="F1">1A</xref> shows a schematic representation of transcription of the mouse mitochondrial DNA (mtDNA) from the heavy strand promoter (blue) and the light strand promoter (red). Segments originated from the 16S gene are processed to give rise to SncmtRNA and the ASncmtRNAs (Figure <xref ref-type="fig" rid="F1">1A</xref> and <xref ref-type="fig" rid="F1">1B</xref>). A schematic of the structures of murine ASncmtRNA-1 and -2 are shown in Figure <xref ref-type="fig" rid="F1">1B</xref> [<xref rid="R11" ref-type="bibr">11</xref>], where the relative position of ASO-1232S, modified with phosphorothioate internucleosidic linkages [<xref rid="R26" ref-type="bibr">26</xref>] used in this study is indicated. Fluorescence <italic>in situ</italic> hybridization (FISH) showed that normal epithelial cells freshly isolated from mouse kidney (mKEC) express the SncmtRNA and the ASncmtRNAs transcripts (Figure <xref ref-type="fig" rid="F1">1C</xref>). In contrast, RenCa cells express the SncmtRNA and downregulate the ASncmtRNAs, similar to human and other mouse tumor cells (Figure <xref ref-type="fig" rid="F1">1C</xref>) [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>].</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Expression of the mSncmtRNA and the mASncmtRNAs in normal mouse kidney epithelial cells (mKEC) and RenCa cells</title><p><bold>A</bold>. Scheme depicting the putative origin of the mouse ncmtRNAs. Segments generated from bidirectional transcription of the 16S region of the mouse mtDNA are processed to give rise to the SncmtRNA and the ASncmtRNAs. In blue, heavy-strand transcript; in red, light-strand transcript. <bold>B</bold>. Schematic representation of the mASncmtRNA-1 and -2, indicating the size of the loop, the length of the IR and position of ASO-1232S used in this study. <bold>C.</bold> FISH of mSncmtRNA and the mASncmtRNAs in RenCa and mKEC cells (Bars = 25 &#x003bc;m).</p></caption><graphic xlink:href="oncotarget-08-43692-g001"/></fig></sec><sec id="s2_2"><title>ASK induces inhibition of cell proliferation</title><p>ASK induces a drastic inhibition of RenCa cell proliferation (Figure <xref ref-type="fig" rid="F2">2A</xref>). At 48 h post-treatment, ASO-1232S induces massive (70%) cell death, as determined by propidium iodide (PI) exclusion, compared to controls (Figure <xref ref-type="fig" rid="F2">2B</xref>). In contrast, viability of normal mKEC cells remains unaffected by the same treatment (Figure <xref ref-type="fig" rid="F2">2C</xref>). Figure <xref ref-type="fig" rid="F2">2D</xref> confirms knockdown of the ASncmtRNA-1 and -2 in RenCa cells.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>ASK induces inhibition of proliferation and death of RenCa cells</title><p><bold>A</bold>. RenCa cells (100,000/ well) were transfected in triplicate with 100 nM of ASO-C, or ASO-1232S or left untreated (NT). At 24, 48 and 72 h post-transfection, total cell number was determined. At 72 h, ASO-1232S induced drastic inhibition of cell proliferation compared to controls (*<italic>p</italic> &#x0003c; 0.005). <bold>B</bold>. Cells were treated as in (A) for 48 h. ASK induced over 70% cell death evaluated by PI staining and cytometric analysis (*<italic>p</italic> &#x0003c; 0,05). <bold>C</bold>. ASK of normal mKEC for 48 h does not induce significant death, compared to controls. <bold>D</bold>. After a 48 h treatment, knockdown of the ASncmtRNAs was confirmed by RT-PCR amplification of mASncmtRNA-1 (648 bp amplicon) and mASncmtRNA-2 (209 bp amplicon), using 18S rRNA (180 bp amplicon) as control (M, 100-bp ladder).</p></caption><graphic xlink:href="oncotarget-08-43692-g002"/></fig></sec><sec id="s2_3"><title>ASK induces apoptotic cell death of RenCa cells</title><p>Cell death by apoptosis was corroborated by different determinations [<xref rid="R27" ref-type="bibr">27</xref>]. One of the early stages of cell death by apoptosis is dissipation of mitochondrial membrane potential (&#x00394;&#x003a8;m) [<xref rid="R28" ref-type="bibr">28</xref>&#x02013;<xref rid="R30" ref-type="bibr">30</xref>]. RenCa cells were transfected with ASO-1232S or ASO-C or left untreated or treated with staurosporine (STP) for 24 h as positive control. Cells were harvested and analyzed by flow cytometry (Materials and Methods). Treatment with STP or ASO-1232S induced a marked dissipation of &#x00394;&#x003a8;m, compared to controls (Figure <xref ref-type="fig" rid="F3">3A</xref>). Three independent experiments showed that ASK and STP induce between 50 and 60% dissipation of &#x00394;&#x003a8;m compared to around 10% in controls (Figure <xref ref-type="fig" rid="F3">3A</xref>). To determine if ASK also induces DNA fragmentation, RenCa cells were transfected for 48 h with ASO-C, or ASO-1232S or left untreated. Fluorescent TUNEL assay, using STP as positive control, shows that ASK or STP treatment induces DNA fragmentation (Figure <xref ref-type="fig" rid="F3">3B</xref>, <xref ref-type="fig" rid="F3">3C</xref>). ASK also induces translocation of phosphatidylserine to the outer layer of the plasma membrane, evidence by an increase in the Annexin V-positive population (Figure <xref ref-type="fig" rid="F3">3D</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>ASK induces apoptosis in RenCa cells</title><p><bold>A</bold>. ASK induces dissipation of &#x00394;&#x003c8;m. RenCa cells were transfected with 100 nM ASO-C or ASO-1232S or left untreated (NT). As positive control, a parallel culture was incubated with STP. At 24 h post-transfection, cells were harvested, stained with 20 nM TMRM for 15 min and analyzed by flow cytometry. Both ASK and STP induce dissipation of &#x00394;&#x003c8;m compared to controls. A triplicate analysis showed that ASK induced around 70% of depolarized cells and STP about 55%, compared to controls (*<italic>p</italic> &#x0003c; 0.001). <bold>B</bold>., <bold>C</bold>. ASK induces DNA fragmentation. RenCa cells treated as in (A) for at 48 h were fixed, subjected to fluorescent TUNEL assay and counterstained with DAPI (see Materials and Methods). As positive control, cells were treated with 1 &#x003bc;M STP. ASK and STP but not controls induced marked DNA fragmentation (Bars = 25 &#x003bc;m). A triplicate analysis shows that ASK and STP induce about 80% and 70% DNA fragmentation, respectively (*<italic>p</italic> &#x0003c; 0.05). <bold>D</bold>. ASK induces translocation of phosphatidylserine to the outer layer of the plasma membrane. RenCa cells treated as in (A) for 24 h were fixed and stained with Annexin-V-Alexa fluor 488 and analyzed by flow cytometry. ASK induced a drastic increase in Annexin V-positive cells, compared to controls (*<italic>p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="oncotarget-08-43692-g003"/></fig><p>ASK also induces activation of apoptotic factors and downregulation of anti-apoptotic factors. RenCa cells were treated as before (Figure <xref ref-type="fig" rid="F3">3A</xref>) for 48 h and Western blot analysis indicate that pro-caspase-3 and -9 and PARP1 were processed after ASK (Figure <xref ref-type="fig" rid="F4">4A</xref>). In addition, the anti-apoptotic factors Bcl-xL and Bcl-2 were also downregulated by ASK (Figure <xref ref-type="fig" rid="F4">4B</xref>). Similarly, another anti-apoptotic factor, survivin, was also strongly downregulated after ASK (Figure <xref ref-type="fig" rid="F4">4C</xref>, <xref ref-type="fig" rid="F4">4D</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>ASK induces activation of pro-apopototic factors and downregulation of anti-apoptotic factors</title><p><bold>A</bold>. RenCa cells were transfected with 100 nM ASO-C or ASO-1232S or left untreated (NT) for 48 h, harvested and processed for Western blot using calnexin as loading control. ASK induces processing of procaspase-3, procaspase-9 and PARP1. <bold>B</bold>. ASK induces downregulation of the anti-apoptotic factors Bcl-xL and Bcl-2 compared to controls; &#x003b2;-actin and calnexin were used as loading controls. <bold>C</bold>. RenCa cells treated as in (A) for 24 h displayed a drastic reduction in survivin, compared to controls, which was around 85% as evidenced by a triplicate densitometric analysis (<bold>D</bold>.; *<italic>p</italic> &#x0003c; 0.005). <bold>E.</bold> Western blot analysis of mKEC cells treated as in (A) for 48 h showed that ASK did not affect PARP1, procaspase-3 or procaspase-9, compared to controls. <bold>F</bold>. ASK did not induce downregulation of Bcl-2 or Survivin in mKEC cells. In E and F, calnexin and &#x003b2;-tubulin were used as loading controls.</p></caption><graphic xlink:href="oncotarget-08-43692-g004"/></fig><p>Figure <xref ref-type="fig" rid="F2">2C</xref> shows that ASK does not induce cell death of mKEC cells according to permeability to PI. In addition, ASK does not induce processing of PARP1, procaspase-3 or procaspase-9 after 48 h of treatment (Figure <xref ref-type="fig" rid="F4">4E</xref>). Similarly, PARP1, Bcl-2 and Survivin are not reduced ASK in these cells (Figure <xref ref-type="fig" rid="F4">4F</xref>).</p></sec><sec id="s2_4"><title>ASK induces inhibition of colony formation and cell invasion</title><p>A noteworthy property of transformed cells is the capacity of anchorage-independent growth and colony formation is considered a parameter of tumorigenesis [<xref rid="R31" ref-type="bibr">31</xref>]. RenCa cells were transfected with ASO-1232S or ASO-C or left untreated (NT) for 48 h. Cells were harvested, counted and 1000 Trypan blue-negative cells were seeded in soft agar in 12-well plates as described (see Materials and Methods). After 2-3 weeks in culture, colonies over 50 &#x003bc;m in diameter were counted and the results show that ASK induces a drastic inhibition of colony formation (Figure <xref ref-type="fig" rid="F5">5A</xref>).</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>ASK inhibits tumorogenic and metastatic potential of RenCa cells</title><p><bold>A</bold>. RenCa cells were transfected with 100 nM ASO-C or ASO-1232S or left untreated (NT) for 48 h. After harvesting and counting, 2,000 Tb-negative cells were seeded in soft agar (see Materials and Methods) and colonies &#x0003e;50 &#x003bc;m in diameter were scored at 2-3 weeks. A triplicate analysis showed that ASK inhibited colony formation by about 90% (*<italic>p</italic> &#x0003c; 0.005). <bold>B</bold>. ASK downregulates proteins involved in metastasis. RenCa cells were transfected as in (A) for 24 h and protein extracts were analyzed by Western blot with antibodies against N-cadherin and P-cadherin, using &#x003b2;-tubulin as loading control. Both cadherins were strongly downregulated by ASK. <bold>C</bold>. ASK inhibits invasiveness of RenCa cells. Cells (100,000) treated as in (A) for 48 h were grown over Matrigel-coated inserts. After 24 h, inserts were fixed in cold methanol, stained with DAPI and mounted in Mowiol. At least 10 fields were evaluated by fluorescence microscopy (Bars = 25 &#x003bc;m). A triplicate analysis showed that ASK induced an inhibition of around 90% in invasiveness of RenCa cells (*<italic>p</italic> &#x0003c; 0,001).</p></caption><graphic xlink:href="oncotarget-08-43692-g005"/></fig><p>To determine whether ASK affects the invasion capacity of RenCa cells, cells were transfected with ASO-C, ASO-1232S or left untreated for 24 h (see Materials and Methods). ASK induced a significant reduction in the expression levels of the epithelial-mesenchymal transition (EMT) markers, N-cadherin [<xref rid="R32" ref-type="bibr">32</xref>] and P-cadherin [<xref rid="R33" ref-type="bibr">33</xref>] (Figure <xref ref-type="fig" rid="F5">5B</xref>), suggesting that the treatment negatively affects metastatic capacity. This was reflected by a lower invasive potential as observed when cells were seeded onto Matrigel [<xref rid="R14" ref-type="bibr">14</xref>] after a 24 h treatment as above. ASK induced around 80% inhibition of invasion, compared to controls (Figure <xref ref-type="fig" rid="F5">5C</xref>).</p></sec><sec id="s2_5"><title>ASK <italic>in vivo</italic> induces reversal of RenCa tumor growth and increased survival</title><p>The above results suggest ASK as a strategy for <italic>in vivo</italic> treatment of renal cancer. Therefore, we performed ASK <italic>in vivo</italic> using a subcutaneous (sc) syngeneic model of RCC with immunocompetent Balb/C mice (Figure <xref ref-type="fig" rid="F6">6A</xref>). RenCa cells (200,000 cells/mouse) were inoculated subcutaneously on the left flank of Balb/C mice (see Materials and Methods). On day 10 post-cell inoculation, mice with tumors of about 100 mm<sup>3</sup> were randomized into three groups of 4 mice each (Figure <xref ref-type="fig" rid="F6">6B</xref>), which were injected intraperitoneally (ip), in a blinded fashion, every other day with 10 doses of 250 &#x003bc;l saline alone or containing 200 &#x003bc;g ASO-C or ASO-1232S (Figure <xref ref-type="fig" rid="F6">6B</xref>). In one representative assay, on day 28 post-cell inoculation both control groups displayed tumors between 1,000 and 1,200 mm<sup>3</sup> and were euthanized (Figure <xref ref-type="fig" rid="F6">6B</xref>). The ASO-1232S-treated group reached a maximum tumor growth of around 700 mm<sup>3</sup> at day 32 and afterwards tumor size progressively diminished in size and disappeared in all mice from this group (Figure <xref ref-type="fig" rid="F6">6B</xref>). The Kaplan-Meier analysis shows 24 and 26-day median survival for saline and ASO-C groups, respectively, whereas all mice treated with ASO-1232S were alive and healthy at 150 days post-cell inoculation (Figure <xref ref-type="fig" rid="F6">6C</xref>), when the experiment was terminated.</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>ASK inhibits subcutaneous RenCa tumor growth</title><p><bold>A</bold>. Experimental scheme. <bold>B</bold>. Twelve Balb/C mice were inoculated sc with 200,000 RenCa cells. At 10 days post-cell inoculation, mice harbored tumors of about 100 mm<sup>3</sup>. Animals were randomized into 3 groups of 4 mice, which received 10 ip injections of 200 &#x003bc;l saline alone or containing 200 &#x003bc;g ASO-C or ASO-1232S. At day 26 post-cell inoculation, the control groups reached tumors over 1000 mm<sup>3</sup> and were sacrificed. The remaining mice reached different tumor size followed by progressive decrease of tumor volume. These four mice were healthy at day 150 post-cell inoculation. <bold>C</bold>. Kaplan-Meier survival curve. Saline and ASO-C control groups displayed 24 and 26-day mean survival, respectively, whereas all ASO-1232S-treated mice were alive and healthy at 150 days post-cell inoculation (<italic>p</italic> = 0.00051).</p></caption><graphic xlink:href="oncotarget-08-43692-g006"/></fig><p>To determine the effects of ASK <italic>in vivo</italic> at the molecular level, a second assay was carried out as described before by sc injection of 8 Balb/C mice with 200,000 RenCa cells. When tumor volumes reached about 200 mm<sup>3</sup>, mice were randomized into 2 groups which were injected ip on days 11, 13, 15, 17, 19 and 21 with 200 &#x003bc;g ASO-C or ASO-1232S in 250 &#x003bc;l saline (Figure <xref ref-type="fig" rid="F7">7A</xref>). The day after the last injection, mice were sacrificed and tumors were collected to prepare lysates. Mice treated with ASO-1232S displayed a strong retardation of tumor growth, compared to the control group (Figure <xref ref-type="fig" rid="F7">7B</xref>). Western blot of the tumors from ASO-1232S-treated mice showed downregulation of survivin compared to the control group (Figure <xref ref-type="fig" rid="F7">7C</xref>, <xref ref-type="fig" rid="F7">7D</xref>). Matrix metallopeptidase 9 (MMP-9), another factor, important in metastatic potential of tumor cells [<xref rid="R34" ref-type="bibr">34</xref>], was also strongly downregulated (Figure <xref ref-type="fig" rid="F7">7E</xref>).</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>ASK <italic>in vivo</italic> induces downregulation of survivin and MMP9</title><p>Eight Balb/c mice were inoculated sc with 200,000 RenCa cells. Eleven days post-cell inoculation, mice contained tumors of about 200 mm<sup>3</sup> and were randomized into 2 groups of 4 mice, which were treated by 6 ip injections on days 11, 13, 15, 17, 19 and 21 with 200 &#x003bc;g ASO-C or ASO-1232S in 200 &#x003bc;l saline. The day after the last injection, mice were euthanized and tumors were harvested and processed for Western blot. <bold>A</bold>. Scheme of the experiment. <bold>B</bold>. Growth curve of sc tumors, showing a drastic retardation in ASO-1232S treated mice, compared to controls. <bold>C</bold>. Representative blot of survivin in lysates of 3 tumors from each group. Tumors treated with ASO-1232S (T4, T5 and T6) exhibited downregulation of survivin, compared to ASO-C tumors (T1, T2 and T3). <bold>D</bold>. A triplicate analysis showing that ASK induced about 80% downregulation of survivin (*<italic>p</italic> &#x0003c; 0,001). <bold>E</bold>. Drastic downregulation of MMP-9 induced by ASK (*<italic>p</italic> &#x0003c; 0.0005).</p></caption><graphic xlink:href="oncotarget-08-43692-g007"/></fig></sec><sec id="s2_6"><title>Orthotopic studies</title><p>The results in Figure <xref ref-type="fig" rid="F6">6</xref> and <xref ref-type="fig" rid="F7">7</xref> provide a strong proof-of-concept supporting the anti-tumor and anti-metastatic effect of ASO-1232S on RenCa cells <italic>in vivo</italic>. However, the sc model for this cell line does not reflect the renal microenvironment from which RenCa cells were derived. Therefore, we used an orthotopic model previously described [<xref rid="R35" ref-type="bibr">35</xref>&#x02013;<xref rid="R37" ref-type="bibr">37</xref>]. As a first step, we determined RenCa tumor growth kinetics. Twenty one Balb/C mice were injected with 100,000 RenCa cells orthotopically into the subcapsular space of the left kidney. On days 4, 6, 8, 10, 12, 14 and 18, three mice were euthanized and both kidneys were removed, weighed and fixed. Four sections were obtained from each left kidney and stained with H&#x00026;E. At day 4 post-cell inoculation, tumors between 2 and 3 mm<sup>3</sup> were detected in the left kidney, growing progressively until day 18 (Figure <xref ref-type="fig" rid="F8">8A</xref>). To determine whether ASO-1232S enters the tumor <italic>in vivo</italic>, mice with orthotopic RenCa tumors were injected once ip with 100 &#x003bc;g Alexa-488-labeled ASO-1232S at day 12 post-cell inoculation. After 2 h, mice were sacrificed and the left kidney was frozen and cryostat-sectioned. The normal kidney parenchyma and the solid RenCa tumor appeared fluorescent, confirming entry of Alexa-488-ASO-1232S into the tissue (Figure <xref ref-type="fig" rid="F8">8B</xref>).</p><fig id="F8" orientation="portrait" position="float"><label>Figure 8</label><caption><title>Kinetics of orthotopic RenCa tumor growth and tumoral 1232S entry</title><p><bold>A</bold>. Twenty one Balb/C mice were inoculated into the subcapsular structure of the kidney with 100,000 RenCa cells. Three mice each were sacrificed on days 4, 6, 8, 10, 12, 14 and 18 and kidneys were fixed. Four sections from each kidney were used to evaluate tumor growth. At day 4, 1-2 mm<sup>3</sup> tumors were found (insert, magnification 4X). <bold>B</bold>. Incorporation of ASO-1232S into orthotopic tumors. RenCa cells (100,000) were injected into the subcapsular region of the left kidney of 2 Balb/C mice and sutured. On day 12 post-cell inoculation, one mouse was injected ip with 100 &#x003bc;g ASO-1232S conjugated to Alexa Fluor 488 and the other mouse was injected with saline. Two h after injection, mice were sacrificed, kidneys were collected, frozen at -70&#x000b0;C and sectioned with a cryostat. Sections were counterstained with DAPI and analyzed by fluorescence microscopy. Green fluorescence was found in the kidney parenchyma and in the tumor only of the mouse injected with Alexa 488-ASO-1232S (magnification 4X).</p></caption><graphic xlink:href="oncotarget-08-43692-g008"/></fig><p>In order to determine the <italic>in vivo</italic> effect of ASO-1232S on orthotopic tumors, 10 Balb/C mice were inoculated as described above. After 4 days, the animals were randomized into 2 groups of 5 mice each and ip injected in a blinded fashion on days 4, 6, 8, 10, 12, 14, 16 and 18 with 250 &#x003bc;l saline containing 200 &#x003bc;g of either ASO-C (control) or ASO-1232S (Figure <xref ref-type="fig" rid="F9">9A</xref>). On day 19 post-cell inoculation, mice were euthanized and the lungs and both kidneys were removed and fixed. In one representative assay and, in contrast to the control group which contained large renal tumors, 4 mice treated with ASO-1232S showed total absence of tumor, while one mouse contained a small tumor (Figure <xref ref-type="fig" rid="F9">9B</xref>, arrows). Tumor weight was estimated subtracting the right kidney from the left kidney showing that ASK was higly effective in inhibiting tumor growth (Figure <xref ref-type="fig" rid="F9">9C</xref>). The number of lung metastatic nodules in animals treated with ASO-1232S was considerably and significantly lower than the controls (Figure <xref ref-type="fig" rid="F9">9D</xref>, <xref ref-type="fig" rid="F9">9E</xref>).</p><fig id="F9" orientation="portrait" position="float"><label>Figure 9</label><caption><title>ASK <italic>in vivo</italic> inhibits primary tumor growth and lung metastasis in an orthotopic renal cancer model</title><p><bold>A</bold>. Scheme of the orthotopic protocol. Ten female Balb/C mice were injected under the renal capsule with 100 &#x003bc;l saline containing 100,000 RenCa cells and sutured. At day 4 post-cell inoculation, mice were randomized into 2 groups of 5 mice each, receiving 8 ip injections on days 4, 6, 8, 10, 12, 14, 16 and 18 of 250 &#x003bc;l saline containing 200 &#x003bc;g of ASO-C or ASO-1232S. On day 19 post-cell inoculation, mice were sacrificed under anesthesia and both kidneys and lungs were resected and fixed. Kidneys were weighed before fixing. <bold>B</bold>. Macroscopic presence of kidney tumors comparing the left and the right (control) kidney (arrows) of each mouse. Only one mouse from the ASO-1232S group developed a small tumor, whereas all 5 mice form the ASO-C group displayed large tumors. <bold>C</bold>. Tumor weight of the left kidney, comparing ASO-C and ASO-1232S (**<italic>p</italic> &#x0003c; 0.005). <bold>D</bold>. Four sections from each fixed lung were stained with H&#x00026;E and metastatic nodules (arrows) were microscopically scored. The figure shows representative images from the left kidney of each mouse (magnification 4X). <bold>E</bold>. ASK induces a low number of metastatic nodules as compared to the control ASO-C (**<italic>p</italic> &#x0003c; 0.005).</p></caption><graphic xlink:href="oncotarget-08-43692-g009"/></fig></sec><sec id="s2_7"><title>Metastasis assay</title><p>To directly assess the effect of ASO-1232S on metastasis, we performed a &#x0201c;classic&#x0201d; <italic>in vivo</italic> metastasis assay [<xref rid="R38" ref-type="bibr">38</xref>]. Fifteen Balb/C mice were injected through the tail vein with 100,000 RenCa cells in 100 &#x003bc;l sterile saline. Mice were then divided into 3 groups, which received 7 ip injections on days 1, 3, 5, 7, 9, 11 and 13 of 250 &#x003bc;l sterile saline alone, or containing 200 &#x003bc;g ASO-C or ASO-1232S (Figure <xref ref-type="fig" rid="F10">10A</xref>). On day 15, mice were euthanized and lungs were collected and fixed (Figure <xref ref-type="fig" rid="F10">10A</xref>). In one representative result, lungs of ASO-1232S-treated mice displayed a considerably and significantly lower number and size of lung metastatic nodules, compared to both control groups (Figure <xref ref-type="fig" rid="F10">10B, 10C</xref>). In a parallel tail-vein metastasis assay, ASO-1232S treatment induced 60% survival for 100 days, compared to the saline control group (Figure <xref ref-type="fig" rid="F10">10D</xref>).</p><fig id="F10" orientation="portrait" position="float"><label>Figure 10</label><caption><title>Tail vein RenCa metastasis assay</title><p><bold>A</bold>. Scheme of the metastasis protocol. Fifteen female Balb/c mice were inoculated through the tail vein with 100 &#x003bc;l saline containing 100,000 RenCa cells and animals were randomized into 3 groups of 5 mice each, which received 7 ip injections on days 1, 3, 5, 7, 9, 11 and 13 of 250 &#x003bc;l saline alone (S) or containing 200 &#x003bc;g ASO-C or ASO-1232S. On day 15, mice were sacrificed and lungs were excised, fixed and sections stained with H&#x00026;E. <bold>B</bold>. Saline and ASO-C-treated mice harbored abundant metastatic nodules (arrows) in the lungs, whereas the ASK group displayed considerably fewer nodules (magnification 4X). <bold>C</bold>. Metastatic nodule count depicts an important and statistically significant reduction in the number of metastatic nodules in the ASK group, compared to both controls (*<italic>p</italic> &#x0003c; 0.005). <bold>D</bold>. Metastasis survival assay. Ten mice were inoculated with 100,000 RenCa cells as described in (A). On day 1 post-cell inoculation, mice were randomized into 2 groups of 5 mice each, which were injected ip with 200 &#x003bc;g ASO-C or ASO-1232S in 250 &#x003bc;l saline, on days 1, 3, 5, 7, 9, 11 and 13. Tumor growth and survival was monitored until day 100 post-cell inoculation (<italic>p</italic> = 0.07).</p></caption><graphic xlink:href="oncotarget-08-43692-g010"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>These results corroborate our previous proposal that downregulation of the ASncmtRNAs seems to be a general hallmark of cancer [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref>]. The mechanism underlying downregulation of the ASncmtRNAs is not clear, but we determined the fate of these transcripts in human foreskin keratinocytes immortalized with Human Papilloma virus (HPV). The results indicated that the E2 viral oncogene of high risk HPV 16 and HPV 18 induces downregulation of the ASncmtRNAs [<xref rid="R13" ref-type="bibr">13</xref>].</p><p>Here we show that knockdown of the ASncmtRNAs or ASK induces RenCa cell death by classical hallmarks of apoptosis <italic>in vitro</italic> and <italic>in vivo</italic>. Hypothetically, the lower copy number of ASncmtRNA in tumor cells renders them more vulnerable to ASK. Indeed, the same treatment does not affect viability of normal murine epithelial cells (mKEC), as observed previously with other mouse and human normal cells [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>], supporting the selective and innocuous nature of this approach.</p><p>An intriguing issue is why the ASncmtRNAs are not suppressed completely in cancer cells. Previously we proposed that these transcripts may function as tumor suppressors [<xref rid="R11" ref-type="bibr">11</xref>&#x02013;<xref rid="R13" ref-type="bibr">13</xref>] and perhaps the low copy number of ASncmtRNAs may be crucial to override cell cycle control mechanisms and thus to fuel cancer progression, by switching to a pro-survival function. This switch from tumor suppressor to oncogene function has been described before. For example, the missense mutation of p53 (mp53), existing in approximately 50% of human cancers, confers oncogenic properties to mp53 that contribute to cancer progression and metastasis [<xref rid="R39" ref-type="bibr">39</xref>&#x02013;<xref rid="R41" ref-type="bibr">41</xref>].</p><p>Apoptosis of RenCa cells induced by ASK is potentiated by downregulation of survivin <italic>in vitro</italic> (Figure <xref ref-type="fig" rid="F4">4C, 4D</xref>) and <italic>in vivo</italic> (Figure <xref ref-type="fig" rid="F7">7C, 7D</xref>), and Bcl-2 and Bcl-xL, members of another family of anti-apoptotic factors (Figure <xref ref-type="fig" rid="F4">4B</xref>) [<xref rid="R42" ref-type="bibr">42</xref>]. Similar results were obtained with human tumor cell lines and the B16F10 murine melanoma cell line [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>]. ASK also induces molecular effects which result detrimental to metastatic potential, such as downregulation of N-cadherin, P-cadherin (Figure <xref ref-type="fig" rid="F5">5B</xref>) and MMP9 (Figure <xref ref-type="fig" rid="F7">7E</xref>), further strengthening the potential of this strategy for RCC therapy. To explain this observed pleiotropic effect in RenCa cells, we have proposed that ASK induces upregulation of microRNAs (miRs) derived from the ASncmtRNAs [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R43" ref-type="bibr">43</xref>, <xref rid="R44" ref-type="bibr">44</xref>].</p><p>Our <italic>in vivo</italic> studies in a sc syngeneic model of RenCa cells show complete reversal of tumor growth (Figure <xref ref-type="fig" rid="F6">6B</xref>). At 150 days post-cell inoculation, animals appeared healthy, in contrast to mice treated with saline or ASO-C. Next, we performed an orthotopic assay of murine RCC by injection of RenCa cells into the subcapsular region of the left kidney. Treatment commenced at 4 days post-cell inoculationy and on day 19, mice were euthanized and both kidneys were recovered together with lungs and fixed. Macroscopic analysis showed that all the control mice contained tumors of different size (Figure <xref ref-type="fig" rid="F9">9B, 9C</xref>). In contrast, only one mouse treated with ASO-1232S exhibited a small tumor (Figure <xref ref-type="fig" rid="F9">9B</xref>). Histological analysis of four sections from each lung showed that control mice treated with ASO-C contained several and large metastatic nodules (Figure <xref ref-type="fig" rid="F9">9D, 9E</xref>). In contrast, only two lungs of mice treated with ASO-1232S contained metastatic nodules, which were significantly fewer and smaller (Figure <xref ref-type="fig" rid="F9">9D, 9E</xref>).</p><p>Tail vein injection of RenCa cells also demonstrated the potent effect of ASK to inhibit lung metastasis. ASK significantly reduced the number of metastatic nodules in the lungs (Figure <xref ref-type="fig" rid="F10">10B, 10C</xref>). In addition, a similar assay showed that ASK induces 60% survival of mice (3 out of 5) until 100 days post-cell inoculation (see Figure <xref ref-type="fig" rid="F10">10D</xref>), when the experiment was finalized. Metastasis is a complex process that requires several factors (proteins and ncRNAs) that cooperatively induce the invasive capacity of tumor cells. Among these factors, survivin, besides its participation as an anti-apoptotic factor and in cell division, is an active player in metastasis [<xref rid="R21" ref-type="bibr">21</xref>]. On the other hand, epithelial-mesenchymal transition (EMT) requires a switch from E-cadherin to N-cadherin [<xref rid="R45" ref-type="bibr">45</xref>&#x02013;<xref rid="R49" ref-type="bibr">49</xref>]. Here we show that ASK induces inhibition of the invasive capacity of RenCa cells (Figure <xref ref-type="fig" rid="F5">5C</xref>), together with downregulation of survivin (Figure <xref ref-type="fig" rid="F4">4C, 4D</xref>), N-cadherin, P-cadherin (Figure <xref ref-type="fig" rid="F5">5B</xref>) and MMP9 (Figure <xref ref-type="fig" rid="F7">7E</xref>), explaining the decrease in metastatic potential of RenCa cells <italic>in vivo</italic>.</p><p>One of the main difficulties in treating mRCC, besides its chemo- and radioresistance, is its established intratumoral and interpersonal heterogeneity [<xref rid="R50" ref-type="bibr">50</xref>]. One of the advantages of ASK is that the observed effects on tumor cells are independent of the genetic background of the tumor. Thus, ASK induces over 60% cell death <italic>in vitro</italic> in human renal cancer cell lines with wild type (Caki-1 cells) and mutant von Hippel-Lindau tumor suppressor gene (A498 cells), as well as in patient-derived primary cultures of clear cell RCC (V. Borgna, unpublished data).</p><p>The present pre-clinical results with RenCa cells, together with our previous results using the B16F10 murine melanoma model, establish proof-of-concept that the ASncmtRNAs may constitute a potent and selective target to develop a treatment for different types of cancer and positions this approach as an attractive strategy ready for clinical testing. In this respect, the USA Food and Drug Administration (FDA) approved an oligonucleotide directed to the human ASncmtRNAs as IND for a Phase I Clinical Trial for solid tumors, which is currently under way and close to completion at UCSF, California, USA.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Animal studies</title><p>Animal studies were conducted in accordance with the guidelines of Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica (Conicyt), Chile and approved by the Ethical Committee of Fundaci&#x000f3;n Ciencia &#x00026; Vida. Balb/C mice 6-8 weeks of age were obtained from The Jackson Laboratory, (Bar Harbor, ME, USA) and maintained under specific pathogen-free conditions and maintained in a temperature-controlled room with 12/12 h light/dark schedule with food and water <italic>ad libitum</italic>.</p></sec><sec id="s4_2"><title>Cell culture</title><p>RenCa cells, a murine renal adenocarcinoma cell line, have been used extensively as a syngeneic model to test new therapeutic drugs for RCC. In addition, these <italic>in vivo</italic> preclinical studies in normal and immunocompetent mice would have a better impact to be extrapolated to human RCC. RenCa cells were purchased from ATCC (CRL-2947) (Manassas, VI, USA) and cultured according to ATCC guidelines. Upon arrival, cells were expanded and frozen in liquid nitrogen at low passage number. After resucitation, cells were not passaged beyond 6 months. Cultures were checked periodically for mycoplasma using the EZ-PCR Mycoplasma Test Kit (Biological Industries, Beit Haemex Ltd, Israel). To obtain primary cultures of mouse kidney epithelial cells, the renal capsule was removed and 1-2 mm<sup>3</sup> pieces of the renal cortex were dissected. The tissue was washed three times in PBS at room temperature and digested for 4 h at 37&#x000b0;C in RPMI containing 1 mg/ml collagenase I, 2 mg/ml collagenase IV, 1 mg/ml Dispase, 20 &#x003bc;g/ml hyaluronidase and 2000 U/ml DNase I. The cell suspension was centrifuged at 200 x g for 5 min at RT and the pellet was suspended in PBS and again centrifuged for 5 min at 200 x g. The final pellet was suspended in RPMI containing 5% FBS and seeded on collagen I-coated T25 flasks (Nunc, Walthan, MA, USA). Cells were incubated at 37&#x000b0;C and 5% CO<sub>2</sub>. Fibroblasts were removed by differential trypsinization [<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref>].</p></sec><sec id="s4_3"><title><italic>In situ</italic> hybridization</title><p>To detect the mSncmtRNA and the ASncmtRNAs, FISH was performed as described [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>] on murine kidney epithelial cells and RenCa cells using antisense probe (5&#x02019;AATAGGATTGCGCTGTTATCCCTA) and sense probe (5&#x02019;TAGGGATAACAGCGCAATCCTATT), respectively, coupled to Texas red at its 5&#x02019; end (Molecular Probes, Eugene, OR, USA).</p></sec><sec id="s4_4"><title>Cell transfection</title><p>ASOs used in this study were synthesized by BioSearch Inc. (Novato, California, USA) with 100% phosphorothioate (PS) internucleosidic linkages. The ASOs utilized were ASO-1232S (5&#x02019; CCTAACGAGCTTGGTGATAGC) and control ASO (ASO-C) (5&#x02019;AGGTGGAGTGGATTGGGG). Transfection was carried out with 2 &#x003bc;g/ml Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA), according to manufacturer&#x000b4;s directions and using 100 nM of each ASO dissolved in sterile saline.</p></sec><sec id="s4_5"><title>Proliferation and cell viability</title><p>Cell count was performed by Trypan blue (Tb) or propidium iodide (PI) exclusion. PI was added at 1 &#x000b5;g/ml 1 min before flow cytometry on a BD FACS Canto Flow Cytometer (San Jose, CA, USA). For Tb, the number of viable cells was determined counting at least 100 cells per sample in triplicate in a hemocytometer [<xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref>].</p></sec><sec id="s4_6"><title>Conventional RT-PCR amplification</title><p>RNA was extracted with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) as described [<xref rid="R11" ref-type="bibr">11</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>]. To eliminate mtDNA contamination, RNA was treated with TURBO DNA-free (Ambion, Waltham, MA, USA) according to manufacturer's instructions. Reverse transcription was carried out with 100 ng RNA, 100 ng random hexamers for 18S rRNA or 20 pmoles of gene-specific primer (5&#x02019; CCTTACAAATAAGCGCTCTCAAC) for ASncmtRNAs, 0.5 mM each dNTP, 10 mM DTT, and 100U MMLV (Invitrogen, Carlsbad, CA, USA). Reactions were incubated at 25&#x000b0;C for 10 min, 37&#x000b0;C for 60 min and 75&#x000b0;C for 5 min. PCR was carried out in 50 &#x000b5;l containing 2.5 &#x000b5;l cDNA, 0.4 mM each dNTP, 0.8 &#x000b5;M each primer, 3 mM MgCl<sub>2</sub> and 2 U GoTaq (Promega, Madison, WI, USA). The sequences of the primers used were 5&#x02019; ACCGTGCAAAGGTAGCATAATC (for) and 5&#x02019; ATATATACGTACAACCTTCTCTAGG (rev) for mASncmtRNA-1, 5&#x02019; ACCGTGCAAAGGTAGCATAATC (for) and 5&#x02019; TTAAACCTAATAACCTTCTCTAGG (rev) for mASncmtRNA-2 and 5&#x02019; GTAACCCGTTGAACCCCATT (for) and 5&#x02019; CATCCAATCGGTAGTAGCG (rev) for 18S rRNA.</p></sec><sec id="s4_7"><title>Mitochondrial membrane depolarization</title><p>After seeding 50,000 cells/well in 12-well plates, cells were transfected the next day for 24 h as described above. Afterwards, cells were loaded with 20 nM tetramethylrhodamine methyl ester (TMRM, Molecular Probes, Eugene, OR, USA) for 15 minutes at 37&#x000b0;C [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>], harvested and analyzed by flow cytometry on a BD-FACS Canto Flow Cytometer. As positive control, mitochondrial depolarization was elicited using 10 &#x000b5;M of staurosporine (STP).</p></sec><sec id="s4_8"><title>Western blot</title><p>Cells transfected for 24 h were harvested, washed in ice-cold PBS and sedimented at 1,000 x g for 10 min at RT. Pellets were suspended in RIPA buffer (10 mM Tris-HCl pH 7.4, 1% sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate), containing 1 mM PMSF and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MS, USA). Protein concentration was quantified with the Bradford microplate system Gen5TM EPOCH (BioTeK, Winooski, VE, USA) (13). Proteins (30 &#x003bc;g/lane) were resolved by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were probed with antibodies against survivin (rabbit polyclonal; 1:1,000), caspase-3 (rabbit polyclonal; 1:1,000) or caspase-9 (mouse monoclonal; 1:1,000), from Abcam (Cambridge, MA, USA); PARP1 (rabbit polyclonal 1:300), &#x003b2;-tubulin (rabbit polyclonal; 1: 1,000), Bcl-xL, Bcl-2 (mouse monoclonal, 1:1,000) from Cell Signaling (Danvers, MA, USA); N-cadherin 1:1,000 (rabbit polyclonal, Thermo Fisher Scientific, Waltham, MA, USA); P-cadherin (rabbit polyclonal 1:500, Santa Cruz, Biotechnology, Santa Cruz, CA, USA); calnexin (mouse monoclonal, 1:1,000, Novus, Littleton, CO, USA) or &#x003b2;-actin (mouse monoclonal, 1:4,000, Sigma-Aldrich, St. Louis, MS, USA). Primary antibodies were detected using peroxidase-labeled anti-mouse or anti-rabbit IgG (1:5,000, Calbiochem, Billerica, MA, USA). Blots were detected with the EZ-ECL system (Biological Industries, Beit Haemex, Israel). The intensity of each band was quantified using ImageJ software (NIH).</p></sec><sec id="s4_9"><title>TUNEL assay</title><p>The TUNEL procedure was performed using the Dead-End Fluorometric TUNEL kit (Promega, Madison, WI, USA) [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>], according to manufacturer's instructions. As positive control, cells were incubated with STP as described above. Samples were analyzed on an Olympus BX-53 fluorescence microscope.</p></sec><sec id="s4_10"><title>Determination of phosphatidylserine exposure</title><p>Phosphatidylserine (PS) exposure was determined by Annexin-V binding with the APOtarget kit (Invitrogen, Carlsbad, CA, USA), according to manufacturer's directions and analyzed by Flow cytometry or fluorescence microscopy [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>].</p></sec><sec id="s4_11"><title>Colony formation and invasion assay</title><p>Anchorage-independent cell growth was determined by colony formation in soft agar as described [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>]. Untreated RenCa cells (NT) or cells transfected with 100 nM ASO-C or ASO-1232S for 48 h were harvested and 2,000 Tb-negative cells were seeded into 12 well-plates in soft agar. Formation of colonies &#x0003e;50 &#x003bc;m in diameter were scored at 2-3 weeks. For matrigel invasion assay, 10<sup>5</sup> cells treated as above for 48 h were seeded over Matrigel-coated inserts (Matrigel Invasion Chamber 8.0 &#x003bc;m; BD Biosciences, San Jose, CA, USA). After 24 h, inserts were fixed in cold methanol, stained with DAPI and membranes were mounted in Mowiol, and 10 fields per sample were evaluated under an Olympus BX-53 fluorescence microscope at 40x.</p></sec><sec id="s4_12"><title>Subcutaneous model</title><p>To determine the antitumor effect of ASO-1232S, 12 Balb/C mice were routinely injected subcutaneously (sc) with 2 &#x000d7; 10<sup>5</sup> RenCa cells on the right flank. When tumors reached a volume of about 100 mm<sup>3</sup>, mice were randomized into three groups of 4 animals, which received 10 intraperitoneal (ip) injections with 250 &#x003bc;l saline, or 200 &#x003bc;g ASO-C or ASO-1232S in 250 &#x003bc;l of saline every other day. Tumor growth was monitored every other day with a caliper and tumor volumes were calculated on the basis of the formula: tumor volume = length x width x height x 0.5236.</p></sec><sec id="s4_13"><title>Orthotopic assay</title><p>To determine tumor growth kinetics in the kidney, 21 Balb/c mice were injected with 100,000 RenCa cells orthotopically into the subcapsular space of the left kidney [<xref rid="R35" ref-type="bibr">35</xref>&#x02013;<xref rid="R37" ref-type="bibr">37</xref>]. On days 4, 6, 8, 10 and 12, 3 mice were sacrificed under anesthesia and both kidneys were removed and fixed. Four sections were obtained from the left kidney and stained with H&#x00026;E. Four days post-cell inoculation, tumors between 2-3 mm<sup>3</sup> were detected in the kidney, after which they grew progressively in size (Figure <xref ref-type="fig" rid="F8">8A</xref>). Notice that ASO-1232S conjugated to Alexa-448 enters the kidney and the RenCa tumor <italic>in vivo</italic> (Figure <xref ref-type="fig" rid="F8">8B</xref>). Next, 10 Balb/C mice were injected orthotopically with 100,000 RenCa cells in the subcapsular space of the left kidney. On day 4, animals were randomized into 2 groups of 5 mice each and ip injected in a blinded fashion on days 4, 6, 8, 10, 12, 14, 16 and 18 with 250 &#x003bc;l saline containing 200 &#x003bc;g ASO-C or ASO-1232S (Figure <xref ref-type="fig" rid="F9">9A</xref>). On day 19 post-cell inoculation, mice were euthanized under anesthesia and the lungs and the right and left kidneys were removed and fixed. Tumor weight was estimated from the difference between the left and right kidney. Four sections from each kidney were stained with H&#x00026;E and analyzed under an Olympus BX-53 microscope.</p></sec><sec id="s4_14"><title>Metastasis assay</title><p>To directly assess the effect of ASO-1232S on metastasis, we performed an <italic>in vivo</italic> metastasis assay [<xref rid="R38" ref-type="bibr">38</xref>]. RenCa cells (100,000/animal) were injected through the tail vein of 15 Balb/C mice, in a total volume of 100 &#x003bc;l sterile saline. Mice were then divided in 3 groups which received 6 ip injections on days 1, 3, 5, 7, 9, 11 and 13, of 250 &#x003bc;l sterile saline alone or containing 200 &#x003bc;g ASO-C or ASO-1232S. On day 15, mice were euthanized and lungs were collected and fixed. Four sections from each lung were stained with H&#x00026;E and evaluated for metastasic nodules.</p></sec><sec id="s4_15"><title>Statistical analysis</title><p>Statistical analysis was performed using Graph Pad Prism version 6.2. One-tailed t-tests and two-way ANOVA tests were used to determine significance between experimental groups. Kaplan-Meier method analysis with log rank sum test was utilized for <italic>in vivo</italic> survival studies. Significance (<italic>p</italic>-value) was set at the nominal level of <italic>p</italic> &#x0003c; 0.1.</p></sec></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>VB, SB, MA, EJ, LLG, VS, CV, LOC, CL and TS carried out experimental procedures. LOB, VB, JV, VAB and OC designed and supervised the study. LOB and VAB wrote the paper.</p></fn></fn-group><ack><p>We thank Dr. Pablo D.T. Valenzuela for his continuous support and enriched discussions.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>LOB holds ownership of equity of Andes Biotechnologies. All other authors declare no potential conflict of interest.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>Universidad Andr&#x000e9;s Bello (DI-421-13/I to VB) and CONICYT, Chile (Fondecyt 1110835 and 1140345 to VAB, Fondecyt 11090060 to CV, Fondecyt 1085210 to JV, Fondef D04I1338 to JV, Fondecyt 11140204 and PAI 7812030019 to LL-G and CCTE-PFB16).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer Statistics</article-title><source>CA Cancer J Clin</source><year>2016</year><volume>66</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">26742998</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungberg</surname><given-names>B</given-names></name><name><surname>Bensalah</surname><given-names>K</given-names></name><name><surname>Canfield</surname><given-names>S</given-names></name><name><surname>Dabestani</surname><given-names>S</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Hora</surname><given-names>M</given-names></name><name><surname>Kuczyk</surname><given-names>MA</given-names></name><name><surname>Lam</surname><given-names>T</given-names></name><name><surname>Marconi</surname><given-names>L</given-names></name><name><surname>Merseburger</surname><given-names>AS</given-names></name><name><surname>Mulders</surname><given-names>P</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Staehler</surname><given-names>M</given-names></name><etal/></person-group><article-title>EAU guidelines on renal cell carcinoma: 2014 update</article-title><source>Eur Urol</source><year>2015</year><volume>67</volume><fpage>913</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">25616710</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamias</surname><given-names>A</given-names></name><name><surname>Tzannis</surname><given-names>K</given-names></name><name><surname>Beuselinck</surname><given-names>B</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Escudier</surname><given-names>S</given-names></name><name><surname>Diosynopoulos</surname><given-names>D</given-names></name><name><surname>Papazisis</surname><given-names>K</given-names></name><name><surname>Lang</surname><given-names>H</given-names></name><name><surname>Wolter</surname><given-names>P</given-names></name><name><surname>de Guillebon</surname><given-names>E</given-names></name><name><surname>Stravodimos</surname><given-names>K</given-names></name><name><surname>Chrisofos</surname><given-names>M</given-names></name><name><surname>Fountzilas</surname><given-names>G</given-names></name><etal/></person-group><article-title>Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration</article-title><source>Br J Cancer</source><year>2013</year><volume>109</volume><fpage>332</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">23807171</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Incovaia</surname><given-names>L</given-names></name><name><surname>Bronte</surname><given-names>G</given-names></name><name><surname>Bazan</surname><given-names>V</given-names></name><name><surname>Badalamenti</surname><given-names>G</given-names></name><name><surname>Rizzo</surname><given-names>S</given-names></name><name><surname>Pantuso</surname><given-names>G</given-names></name><name><surname>Natoli</surname><given-names>C</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name></person-group><article-title>Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>21259</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7267</pub-id><pub-id pub-id-type="pmid">26872372</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Rixe</surname><given-names>O</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Bycott</surname><given-names>PW</given-names></name><name><surname>Baum</surname><given-names>CM</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name></person-group><article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>115</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17215529</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e9;grier</surname><given-names>S</given-names></name><name><surname>Gravis</surname><given-names>G</given-names></name><name><surname>P&#x000e9;rol</surname><given-names>D</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Delva</surname><given-names>R</given-names></name><name><surname>Bay</surname><given-names>JO</given-names></name><name><surname>Blanc</surname><given-names>E</given-names></name><name><surname>Ferlay</surname><given-names>C</given-names></name><name><surname>Geoffrois</surname><given-names>L</given-names></name><name><surname>Rolland</surname><given-names>F</given-names></name><name><surname>Legouffe</surname><given-names>E</given-names></name><name><surname>Sevin</surname><given-names>E</given-names></name><name><surname>Laguerre</surname><given-names>B</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name></person-group><article-title>Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>673</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">21664867</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Regan</surname><given-names>MM</given-names></name><name><surname>Clark</surname><given-names>JI</given-names></name><name><surname>Flaherty</surname><given-names>LE</given-names></name><name><surname>Weiss</surname><given-names>GR</given-names></name><name><surname>Logan</surname><given-names>TF</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>MS</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Ernstoff</surname><given-names>MS</given-names></name><name><surname>Tretter</surname><given-names>CP</given-names></name><name><surname>Urba</surname><given-names>WJ</given-names></name><name><surname>Smith</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>133</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">15625368</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verheul</surname><given-names>HM</given-names></name><name><surname>Hammers</surname><given-names>H</given-names></name><name><surname>van Erp</surname><given-names>K</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Sanni</surname><given-names>T</given-names></name><name><surname>Salumbides</surname><given-names>B</given-names></name><name><surname>Qian</surname><given-names>DZ</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Pili</surname><given-names>R</given-names></name></person-group><article-title>Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>4201</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17634549</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Yoshimura</surname><given-names>K</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Verheul</surname><given-names>H</given-names></name><name><surname>Hammers</surname><given-names>H</given-names></name><name><surname>Sanni</surname><given-names>TB</given-names></name><name><surname>Salumbides</surname><given-names>BC</given-names></name><name><surname>Van Erp</surname><given-names>K</given-names></name><name><surname>Schulick</surname><given-names>R</given-names></name><name><surname>Pili</surname><given-names>R</given-names></name></person-group><article-title>RenCa Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>4538</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17671140</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Esser</surname><given-names>N</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Tsuchihashi</surname><given-names>Z</given-names></name><name><surname>Fiedler</surname><given-names>U</given-names></name><name><surname>Graeser</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name></person-group><article-title>Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma</article-title><source>Anticancer Res</source><year>2012</year><volume>32</volume><fpage>2399</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">22753696</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villegas</surname><given-names>J</given-names></name><name><surname>Burzio</surname><given-names>VA</given-names></name><name><surname>Villota</surname><given-names>C</given-names></name><name><surname>Landerer</surname><given-names>E</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Santander</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Vera</surname><given-names>MI</given-names></name><name><surname>Boccardo</surname><given-names>E</given-names></name><name><surname>Villa</surname><given-names>LL</given-names></name><name><surname>Burzio</surname><given-names>LO</given-names></name></person-group><article-title>Expression of a novel non-coding mitochondrial RNA in human proliferating cells</article-title><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><fpage>7336</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">17962305</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burzio</surname><given-names>VA</given-names></name><name><surname>Villota</surname><given-names>C</given-names></name><name><surname>Villegas</surname><given-names>J</given-names></name><name><surname>Landerer</surname><given-names>E</given-names></name><name><surname>Boccardo</surname><given-names>E</given-names></name><name><surname>Villa</surname><given-names>LL</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>R</given-names></name><name><surname>Lopez</surname><given-names>C</given-names></name><name><surname>Gaete</surname><given-names>F</given-names></name><name><surname>Toro</surname><given-names>V</given-names></name><name><surname>Rodriguez</surname><given-names>X</given-names></name><name><surname>Burzio</surname><given-names>LO</given-names></name></person-group><article-title>Expression of a family of noncoding mitochondrial RNAs distinguishes normal from cancer cells</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>9430</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">19470459</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villota</surname><given-names>C</given-names></name><name><surname>Campos</surname><given-names>A</given-names></name><name><surname>Vidaurre</surname><given-names>S</given-names></name><name><surname>Oliveira-Cruz</surname><given-names>L</given-names></name><name><surname>Boccardo</surname><given-names>E</given-names></name><name><surname>Burzio</surname><given-names>VA</given-names></name><name><surname>Varas</surname><given-names>M</given-names></name><name><surname>Villegas</surname><given-names>J</given-names></name><name><surname>Villa</surname><given-names>LL</given-names></name><name><surname>Valenzuela</surname><given-names>PD</given-names></name><name><surname>Soc&#x000ed;as</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>S</given-names></name><name><surname>Burzio</surname><given-names>LO</given-names></name></person-group><article-title>Expression of mitochondrial ncRNAs is modulated by high-risk HPV oncogenes</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>21303</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22539350</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobos-Gonz&#x000e1;lez</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>S</given-names></name><name><surname>Araya</surname><given-names>M</given-names></name><name><surname>Restovic</surname><given-names>F</given-names></name><name><surname>Javiera Echenique</surname><given-names>J</given-names></name><name><surname>Oliveira-Cruz</surname><given-names>L</given-names></name><name><surname>Fitzpatrick</surname><given-names>C</given-names></name><name><surname>Briones</surname><given-names>M</given-names></name><name><surname>Villegas</surname><given-names>J</given-names></name><name><surname>Villota</surname><given-names>C</given-names></name><name><surname>Vidaurre</surname><given-names>S</given-names></name><name><surname>Borgna</surname><given-names>V</given-names></name><name><surname>Socias</surname><given-names>M</given-names></name><etal/></person-group><article-title>Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>58331</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11110</pub-id><pub-id pub-id-type="pmid">27507060</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidaurre</surname><given-names>S</given-names></name><name><surname>Fitzpatrick</surname><given-names>C</given-names></name><name><surname>Burzio</surname><given-names>VA</given-names></name><name><surname>Briones</surname><given-names>M</given-names></name><name><surname>Villota</surname><given-names>C</given-names></name><name><surname>Villegas</surname><given-names>J</given-names></name><name><surname>Echenique</surname><given-names>J</given-names></name><name><surname>Oliveira-Cruz</surname><given-names>L</given-names></name><name><surname>Araya</surname><given-names>M</given-names></name><name><surname>Borgna</surname><given-names>V</given-names></name><name><surname>Soc&#x000ed;as</surname><given-names>T</given-names></name><name><surname>Lopez</surname><given-names>C</given-names></name><name><surname>Avila</surname><given-names>R</given-names></name><name><surname>Burzio</surname><given-names>LO</given-names></name></person-group><article-title>Down-regulation of the Antisense Mitochondrial ncRNAs is a Unique Vulnerability of Cancer Cells and a Potential Target for Cancer Therapy</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>27182</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">25100722</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohi</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Wilford</surname><given-names>CE</given-names></name><name><surname>Samuel</surname><given-names>T</given-names></name><name><surname>Welsh</surname><given-names>K</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Armstrong</surname><given-names>R</given-names></name><name><surname>Matsuzawa</surname><given-names>S</given-names></name><name><surname>Salvesen</surname><given-names>GS</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>An IAP-IAP complex inhibits apoptosis</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>34087</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15218035</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohi</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection</article-title><source>Mol Cell</source><year>2007</year><volume>27</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">17612487</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Survivin and IAP proteins in cell-death mechanisms</article-title><source>Biochem J</source><year>2010</year><volume>30</volume><fpage>199</fpage><lpage>205</lpage></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>BH</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Pop</surname><given-names>R</given-names></name><name><surname>Dohi</surname><given-names>T</given-names></name><name><surname>Socolovsky</surname><given-names>MC</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Developmental Control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) Involves mitochondrial import of the survivin protein</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>16758</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">21454573</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Survivin- The inconvenient IAP</article-title><source>Semin Cell Dev Biol</source><year>2015</year><volume>39</volume><fpage>91</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">25591986</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flierl</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Cottrell</surname><given-names>B</given-names></name><name><surname>Murdock</surname><given-names>D</given-names></name><name><surname>Seibel</surname><given-names>P</given-names></name><name><surname>Wallace</surname><given-names>DC</given-names></name></person-group><article-title>Targeted Delivery of DNA to the Mitochondrial Compartment via Import Sequence Conjugated Peptide</article-title><source>Nucleic Acid Mol Ther</source><year>2003</year><volume>7</volume><fpage>550</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12727119</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>MF</given-names></name><name><surname>Filipovska</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Gait</surname><given-names>MJ</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group><article-title>Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers</article-title><source>Biochem J</source><year>2004</year><volume>383</volume><fpage>457</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">15270716</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landerer</surname><given-names>E</given-names></name><name><surname>Villegas</surname><given-names>J</given-names></name><name><surname>Burzio</surname><given-names>VA</given-names></name><name><surname>Oliveira</surname><given-names>L</given-names></name><name><surname>Villota</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>C</given-names></name><name><surname>Restovic</surname><given-names>F</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Castillo</surname><given-names>O</given-names></name><name><surname>Burzio</surname><given-names>LO</given-names></name></person-group><article-title>Nuclear localization of the mitochondrial ncRNAs in normal and cancer cells</article-title><source>Cell Oncol (Dordr)</source><year>2011</year><volume>34</volume><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">21347712</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asin-Cayuela</surname><given-names>J</given-names></name><name><surname>Gustafsson</surname><given-names>CM</given-names></name></person-group><article-title>Mitochondrial transcription and its regulation in mammalian cells</article-title><source>Trends Biochem Sci</source><year>2007</year><volume>32</volume><fpage>111</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17291767</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>N</given-names></name><name><surname>Stein</surname><given-names>CA</given-names></name></person-group><article-title>Antisense oligonucleotides: basic concepts and mechanisms</article-title><source>Mol Cancer Ther</source><year>2002</year><volume>1</volume><fpage>347</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12489851</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Morselli</surname><given-names>E</given-names></name><name><surname>Kepp Vitale</surname><given-names>H</given-names></name><name><surname>Rigoni</surname><given-names>A</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Zischka</surname><given-names>H</given-names></name><name><surname>Castedo</surname><given-names>M</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Mitochondrial gateways to cancer</article-title><source>Mol Aspects Med</source><year>2010</year><volume>31</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">19698742</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiskanen</surname><given-names>KM</given-names></name><name><surname>Bhat</surname><given-names>MB</given-names></name><name><surname>Wang</surname><given-names>HW</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Nieminen</surname><given-names>AL</given-names></name></person-group><article-title>Mitochondrial depolarization accompanies cytochrome c release during apoptosis in PC6 cells</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>5654</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10026183</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heerdt</surname><given-names>BG</given-names></name><name><surname>Houston</surname><given-names>MA</given-names></name><name><surname>Augenlicht</surname><given-names>LH</given-names></name></person-group><article-title>Growth properties of colonic tumor cells are a function of the intrinsic mitochondrial membrane potential</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>1591</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16452217</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houston</surname><given-names>MA</given-names></name><name><surname>Augenlicht</surname><given-names>LH</given-names></name><name><surname>Heerdt</surname><given-names>BG</given-names></name></person-group><article-title>Stable differences in intrinsic mitochondrial membrane potential of tumor cell subpopulations reflect phenotypic heterogeneity</article-title><source>Int J Cell Biol</source><year>2011</year><volume>2011</volume><fpage>978583</fpage><pub-id pub-id-type="pmid">21760799</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Trusolino</surname><given-names>L</given-names></name></person-group><article-title>Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth</article-title><source>J Cell Biol</source><year>2006</year><volume>175</volume><fpage>993</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">17158954</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodin</surname><given-names>S</given-names></name><name><surname>Planchon</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>ER</given-names></name><name><surname>Comunale</surname><given-names>F</given-names></name><name><surname>Gauthier-Rouviere</surname><given-names>C</given-names></name></person-group><article-title>Flotillins in intercellular adhesion &#x02013; from cellular physiology to human diseases</article-title><source>J Cell Sci</source><year>2014</year><volume>127</volume><fpage>5139</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">25413346</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>AF</given-names></name><name><surname>Paredes</surname><given-names>J</given-names></name></person-group><article-title>P-cadherin and the journey to cancer met&#x000e1;stasis</article-title><source>Mol Cancer</source><year>2015</year><volume>14</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">25560632</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name></person-group><article-title>Association between Polymorphisms in the Promoter Regions of Matrix Metalloproteinases (MMPs) and Risk of Cancer Metastasis: A Meta-Analysis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Salumbides</surname><given-names>BC</given-names></name><name><surname>Lehet</surname><given-names>KM</given-names></name><name><surname>Ndikuyeze</surname><given-names>G</given-names></name><name><surname>Pili</surname><given-names>R</given-names></name></person-group><article-title>Pre-clinical models of renal carcinoma and their utility in drug development</article-title><source>Curr Protoc Pharmacol</source><year>2009</year><comment>Chapter 14: Unit 14.13</comment><pub-id pub-id-type="doi">10.1002/0471141755.ph1413s47</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salup</surname><given-names>RR</given-names></name><name><surname>Back</surname><given-names>TC</given-names></name><name><surname>Wiltrout</surname><given-names>RH</given-names></name></person-group><article-title>Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy</article-title><source>J Immunol</source><year>1987</year><volume>138</volume><fpage>641</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3491854</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillman</surname><given-names>GG</given-names></name><name><surname>Droz</surname><given-names>JP</given-names></name><name><surname>Haas</surname><given-names>GP</given-names></name></person-group><article-title>Experimental animal models for the study of therapeutic approaches in renal cell carcinoma</article-title><source>In Vivo</source><year>1994</year><volume>8</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">8054515</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>C</given-names></name><name><surname>Hunter</surname><given-names>K</given-names></name></person-group><article-title>Modeling metastasis in vivo</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>513</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15358632</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freed-Pastor</surname><given-names>WA</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><article-title>Mutant p53: one name, many proteins</article-title><source>Genes Dev</source><year>2012</year><volume>26</volume><fpage>1268</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">22713868</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>OC</given-names></name><name><surname>Choudhury</surname><given-names>S</given-names></name><name><surname>Kolukula</surname><given-names>V</given-names></name><name><surname>Vietsch</surname><given-names>EE</given-names></name><name><surname>Catania</surname><given-names>B</given-names></name><name><surname>Preet</surname><given-names>A</given-names></name><name><surname>Reynoso</surname><given-names>K</given-names></name><name><surname>Bargonetti</surname><given-names>J</given-names></name><name><surname>Wellstein</surname><given-names>A</given-names></name><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>Avantaggiati</surname><given-names>ML</given-names></name></person-group><article-title>Dietary down-regulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy</article-title><source>Cell Cycle</source><year>2012</year><volume>11</volume><fpage>4436</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">23151455</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissmueller</surname><given-names>S</given-names></name><name><surname>Manchado</surname><given-names>E</given-names></name><name><surname>Saborowski</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>JP</given-names><suffix>4th</suffix></name><name><surname>Wagenblast</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Moon</surname><given-names>SH</given-names></name><name><surname>Pfister</surname><given-names>NT</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Kitzing</surname><given-names>T</given-names></name><name><surname>Aust</surname><given-names>D</given-names></name><name><surname>Markert</surname><given-names>EK</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mutant p53 drives pancreatic cancer metastasis through cell autonomous PDGF receptor signaling</article-title><source>Cell</source><year>2014</year><volume>157</volume><fpage>382</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">24725405</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besbes</surname><given-names>S</given-names></name><name><surname>Mirshahi</surname><given-names>M</given-names></name><name><surname>Pocard</surname><given-names>M</given-names></name><name><surname>Billard</surname><given-names>C</given-names></name></person-group><article-title>New dimension in therapeutic targeting of BCL-2 family proteins</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>12862</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3868</pub-id><pub-id pub-id-type="pmid">25970783</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracken</surname><given-names>CP</given-names></name><name><surname>Scott</surname><given-names>HS</given-names></name><name><surname>Goodall</surname><given-names>GJ</given-names></name></person-group><article-title>A network-biology perspective of microRNA function and dysfunction in cancer</article-title><source>Nat Rev Genet</source><year>2016</year><volume>17</volume><fpage>719</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">27795564</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>32545</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5324</pub-id><pub-id pub-id-type="pmid">26416448</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>Weinberg</surname><given-names>R</given-names></name></person-group><article-title>The basics of epithelial-mesenchymal transition</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><fpage>1420</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19487818</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Weinberg</surname><given-names>R</given-names></name></person-group><article-title>Epithelial&#x02013;Mesenchymal Plasticity: A Central Regulator of Cancer Progression</article-title><source>Trends Cell Biol</source><year>2015</year><volume>25</volume><fpage>675</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">26437589</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Leung</surname><given-names>E</given-names></name><name><surname>Baguley</surname><given-names>BC</given-names></name><name><surname>Finlay</surname><given-names>GJ</given-names></name></person-group><article-title>Heterogeneity of expression of epithelial&#x02013;mesenchymal transition markers in melanocytes and melanoma cell lines</article-title><source>Front Genet</source><year>2013</year><volume>4</volume><fpage>97</fpage><pub-id pub-id-type="pmid">23755070</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravdal</surname><given-names>K</given-names></name><name><surname>Halvorsen</surname><given-names>O</given-names></name><name><surname>Haukaas</surname><given-names>S</given-names></name><name><surname>Akslen</surname><given-names>L</given-names></name></person-group><article-title>A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and is of Strong and Independent Importance for the Progress of Prostate Cancer</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>7003</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">18056176</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Weinberg</surname><given-names>R</given-names></name></person-group><article-title>Epithelial&#x02013;Mesenchymal Plasticity: A Central Regulator of Cancer Progression</article-title><source>Trends Cell Biol</source><year>2015</year><volume>25</volume><fpage>675</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">26437589</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlinger</surname><given-names>M</given-names></name><name><surname>Rowan</surname><given-names>AJ</given-names></name><name><surname>Horswell</surname><given-names>S</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Endesfelder</surname><given-names>D</given-names></name><name><surname>Gronroos</surname><given-names>E</given-names></name><name><surname>Martinez</surname><given-names>P</given-names></name><name><surname>Matthews</surname><given-names>N</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Tarpey</surname><given-names>P</given-names></name><name><surname>Varela</surname><given-names>I</given-names></name><name><surname>Phillimore</surname><given-names>B</given-names></name><name><surname>Begum</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>883</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22397650</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>L</given-names></name><name><surname>Arranz</surname><given-names>I</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>A</given-names></name><name><surname>Soriano</surname><given-names>L</given-names></name><name><surname>Diebold</surname><given-names>Y</given-names></name></person-group><article-title>A new human primary epithelial cell culture model to study conjunctival inflammation</article-title><source>Invest Ophthalmol Vis Sci</source><year>2013</year><volume>54</volume><fpage>7143</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">24106119</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sordillo</surname><given-names>LM</given-names></name><name><surname>Oliver</surname><given-names>SP</given-names></name><name><surname>Akers</surname><given-names>RM</given-names></name></person-group><article-title>Culture of bovine mammary epithelial cells in D-valine modified medium: selective removal of contaminating fibroblasts</article-title><source>Cell Biol Int Rep</source><year>1988</year><volume>12</volume><fpage>355</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">3401935</pub-id></element-citation></ref></ref-list></back></article>